Back to Search Start Over

Total Diet Replacement Within an Integrated Intensive Lifestyle Intervention for Remission of Type 2 Diabetes: Lessons From DiRECT.

Authors :
Noronha JC
Thom G
Lean MEJ
Source :
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2022 Jun 02; Vol. 13, pp. 888557. Date of Electronic Publication: 2022 Jun 02 (Print Publication: 2022).
Publication Year :
2022

Abstract

The prognosis for people with type 2 diabetes (T2D) remains concerning, yet its seriousness is often underestimated. T2D is a manifestation, in susceptible individuals, of the disease-process of obesity, and at diagnosis, 10-year survival rates for T2D are around 50%. Here, we will examine: (a) the role of weight loss in T2D, (b) use of total diet replacements (TDRs) to induce weight loss, (c) the Diabetes Remission Clinical Trial (DiRECT) protocol and key results, (d) other dietary interventions related to T2D remission, (e) remission in real life, and (f) future directions. Remission of short-duration T2D will usually require 10-15% body weight loss, and results from the DiRECT trial demonstrated that this can be achieved within routine care in nearly half of all people undertaking a supported, TDR-led behavioural weight management programme. In light of these findings, which have since been replicated in the Diabetes Intervention Accentuating Diet and Enhancing Metabolism (DIADEM-I) trial conducted in the Middle East and North Africa, it is now time to prioritize weight loss programmes for T2D remission from diagnosis, and with increasing acceptance and availability of digital healthcare, there is an opportunity to scale up delivery of remission programmes in a cost effective manner.<br />Competing Interests: JN has worked as a clinical research coordinator at INQUIS Clinical Research. He has also received research support from Glycemia Consulting Inc. GT reports funding for PhD fees, conference attendance and departmental research support from Cambridge Weight Plan outside the submitted work. ML has had departmental research funding from Diabetes UK, NIHR, Novo Nordisk, has received personal fees for lecturing and consultancy from Novo Nordisk, Merck, Eli Lilly, Sanofi, Nestle, Oviva, and has provided unpaid medical consultancy to Counterweight Ltd.<br /> (Copyright © 2022 Noronha, Thom and Lean.)

Details

Language :
English
ISSN :
1664-2392
Volume :
13
Database :
MEDLINE
Journal :
Frontiers in endocrinology
Publication Type :
Academic Journal
Accession number :
35721753
Full Text :
https://doi.org/10.3389/fendo.2022.888557